Intervention Review

You have free access to this content

Interventions for preventing neuropathy caused by cisplatin and related compounds

  1. James W Albers1,*,
  2. Vinay Chaudhry2,
  3. Guido Cavaletti3,
  4. Ross C Donehower4

Editorial Group: Cochrane Neuromuscular Disease Group

Published Online: 31 MAR 2014

Assessed as up-to-date: 4 MAR 2013

DOI: 10.1002/14651858.CD005228.pub4


How to Cite

Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD005228. DOI: 10.1002/14651858.CD005228.pub4.

Author Information

  1. 1

    University of Michigan, Department of Neurology, Ann Arbor, USA

  2. 2

    Johns Hopkins Outpatient Center, Neurology, Baltimore, Maryland, USA

  3. 3

    Università degli Studi di Milano-Bicocca, Dipartimento di Chirurgia e Medicina Interdisciplinare, Monza, Italy

  4. 4

    Johns Hopkins University, Division of Medical Oncology, Baltimore, USA

*James W Albers, Department of Neurology, University of Michigan, 1C325/0032 University Hospital, 1500 E. Medical Center Drive, Box 0316, Ann Arbor, MI 48109-0032, USA. jwalbers@umich.edu.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 31 MAR 2014

SEARCH

[Figure 1]
Figure 1. Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Red (-) = high risk of bias; yellow (?) = unclear risk of bias; green (+) = low risk of bias.
[Figure 2]
Figure 2. Forest plot of comparison: 2 Amifostine - neurotoxicity rating, outcome: 2.2 Neurotoxicity rating ≥ 2.
[Figure 3]
Figure 3. Forest plot of comparison: 2 Amifostine - neurotoxicity rating, outcome: 2.3 Neurotoxicity rating ≥ 3.
[Figure 4]
Figure 4. Forest plot of comparison: 5 Ca/Mg - sensory neuropathy (SNP), outcome: 5.1 Chronic NCI-CTC ≥ grade 2.
[Figure 5]
Figure 5. Forest plot of comparison: 11 GSH - NCI NT rating 2-4 at treatment end, outcome: 11.1 Chronic NCI ≥ grade 2.
[Figure 6]
Figure 6. Forest plot of comparison: 20 Vitamin E - SNAP amplitude, outcome: 20.1 Sural amplitude uv after 6 cycles.
[Figure 7]
Figure 7. Forest plot of comparison: 24 Vitamin E - Clinical impairment, outcome: 24.1 Total neuropathy score after 6 cycles.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Amifostine - clinical impairment, Outcome 1 Clinical impairment at 3 months.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Amifostine - functional activities of daily living, Outcome 1 Functonal activities of daily living as measured at 3 months.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Amifostine - neurotoxicity rating, Outcome 1 Neurotoxicity rating ≥ 1.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Amifostine - neurotoxicity rating, Outcome 2 Neurotoxicity rating ≥ 2.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Amifostine - neurotoxicity rating, Outcome 3 Neurotoxicity rating ≥ 3.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Calcium/magnesium - nerve conduction study (NCS) results, Outcome 1 Abnormal sensory nerve action potential.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Calcium/magnesium - sensory neuropathy (SNP), Outcome 1 Oxaliplatin specific sensory neurotoxicity ≥ grade 2.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Calcium/magnesium - sensory neuropathy (SNP), Outcome 2 Chronic NCI-CTC ≥ grade 2.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Calcium/magnesium - sensory neuropathy (SNP), Outcome 3 SNP grade 3.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Diethyldithiocarbamate - National Cancer Institute (NCI) neurotoxicity rating scale, Outcome 1 NCI toxicity for neuropathy.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Glutathione - nerve conduction study (NCS) results, Outcome 1 SSC amplitude.
[Analysis 8.1]
Analysis 8.1. Comparison 8 Glutathione - clinical impairment, Outcome 1 Impairment at 3 months.
[Analysis 9.1]
Analysis 9.1. Comparison 9 Glutathione - Neuropathy Symptom Score (NSS), Outcome 1 NSS symptoms of neuropathy at 3 months.
[Analysis 10.1]
Analysis 10.1. Comparison 10 Glutathione - World Health Organization (WHO) evidence of neurotoxicity, Outcome 1 WHO neurotoxicity during trial.
[Analysis 11.1]
Analysis 11.1. Comparison 11 Glutathione - chronic National Cancer Institute (NCI) toxicity rating, Outcome 1 NCI toxicity at 12 weeks.
[Analysis 12.1]
Analysis 12.1. Comparison 12 Glutathione - National Cancer Institute (NCI) neurotoxicity rating 2-4 at treatment end, Outcome 1 Chronic NCI ≥ grade 2.
[Analysis 13.1]
Analysis 13.1. Comparison 13 Glutathione - other outcomes, Outcome 1 Oliguria.
[Analysis 14.1]
Analysis 14.1. Comparison 14 Org 2766 - qualitative vibration position testing (VPT), Outcome 1 Abnormal VPT at 3 to 5 months.
[Analysis 15.1]
Analysis 15.1. Comparison 15 Org 2766 (1 or 2 mg)- vibration perception testing (VPT) finger or hand, Outcome 1 VPT hand 3 to 5 months post treatment.
[Analysis 16.1]
Analysis 16.1. Comparison 16 Oxcarbazepine - sensory nerve action potential (SNAP) amplitude, Outcome 1 SNAP amplitude: sural.
[Analysis 16.2]
Analysis 16.2. Comparison 16 Oxcarbazepine - sensory nerve action potential (SNAP) amplitude, Outcome 2 SNAP amplitude: superficial peroneal.
[Analysis 16.3]
Analysis 16.3. Comparison 16 Oxcarbazepine - sensory nerve action potential (SNAP) amplitude, Outcome 3 SNAP amplitude: ulnar.
[Analysis 17.1]
Analysis 17.1. Comparison 17 Oxcarbazepine - neurotoxicity rating, Outcome 1 Neuropathy after 12 cycles.
[Analysis 17.2]
Analysis 17.2. Comparison 17 Oxcarbazepine - neurotoxicity rating, Outcome 2 Severity of neuropathy (TNS).
[Analysis 18.1]
Analysis 18.1. Comparison 18 Retinoic acid - National Cancer Institute (NCI) neurotoxicity rating, Outcome 1 NCI-CTC grade ≥ 2.
[Analysis 19.1]
Analysis 19.1. Comparison 19 Vitamin E - qualitative sensory nerve conduction study (NCS) amplitudes, Outcome 1 Abnormal median or sural sensory amplitude.
[Analysis 20.1]
Analysis 20.1. Comparison 20 Vitamin E - sensory nerve action potential amplitude, Outcome 1 Superficial peroneal amp 3 mos s/p treatment.
[Analysis 20.2]
Analysis 20.2. Comparison 20 Vitamin E - sensory nerve action potential amplitude, Outcome 2 Ulnar SNAP amp 3 mos s/p treatment.
[Analysis 20.3]
Analysis 20.3. Comparison 20 Vitamin E - sensory nerve action potential amplitude, Outcome 3 Sural amplitude uv after 6 cycles.
[Analysis 21.1]
Analysis 21.1. Comparison 21 Vitamin E - incidence of neuropathy, Outcome 1 Incidence of peripheral neuropathy (completed trial).
[Analysis 21.2]
Analysis 21.2. Comparison 21 Vitamin E - incidence of neuropathy, Outcome 2 Incidence of peripheral neuropathy (intention to treat).
[Analysis 22.1]
Analysis 22.1. Comparison 22 Vitamin E - modified peripheral neuropathy (PNP) score, Outcome 1 Modified peripheral neuropathy (PNP) score.
[Analysis 23.1]
Analysis 23.1. Comparison 23 Vitamin E - clinical impairment, Outcome 1 Total neuropathy score after 6 cycles.